I
Isamu Okamoto
Researcher at Kyushu University
Publications - 458
Citations - 25482
Isamu Okamoto is an academic researcher from Kyushu University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 64, co-authored 413 publications receiving 19982 citations. Previous affiliations of Isamu Okamoto include Emory University & Kumamoto University.
Papers
More filters
Journal ArticleDOI
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
Masaaki Hibi,Hiroyasu Kaneda,Junko Tanizaki,Kazuko Sakai,Yosuke Togashi,Masato Terashima,Marco A. De Velasco,Yoshihiko Fujita,Eri Banno,Yu Nakamura,Masayuki Takeda,Akihiko Ito,Tetsuya Mitsudomi,Kazuhiko Nakagawa,Isamu Okamoto,Kazuto Nishio +15 more
TL;DR: Screening for FGFR alterations by NGS warrants further study as a means to identify patients with LSCC recurrence after surgery who might benefit from nintedanib therapy and its effects on tumor formation were examined in vivo.
Journal ArticleDOI
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
Hirohito Tada,Tetsuya Mitsudomi,Toshihiro Misumi,Kenji Sugio,Masahiro Tsuboi,Isamu Okamoto,Yasuo Iwamoto,Noriaki Sakakura,Shunichi Sugawara,Shinji Atagi,Toshiaki Takahashi,Hidetoshi Hayashi,Morihito Okada,Hidetoshi Inokawa,Hiroshige Yoshioka,Kazuhisa Takahashi,Masahiko Higashiyama,Ichiro Yoshino,Kazuhiko Nakagawa +18 more
TL;DR: In this paper, the efficacy of gefitinib as an adjuvant therapy for non-small-cell lung cancer patients with EGFR mutation was investigated, and the authors concluded that gefinib was effective in improving lung cancer survival.
Journal ArticleDOI
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L)
Takashi Seto,Koichi Azuma,Takeharu Yamanaka,Shunichi Sugawara,Hiroshige Yoshioka,Kazushige Wakuda,Shinji Atagi,Yasuo Iwamoto,Hidetoshi Hayashi,Isamu Okamoto,Hideo Saka,Shigeki Mitsuoka,Daichi Fujimoto,Kazumi Nishino,Atsushi Horiike,Haruko Daga,Takashi Sone,Nobuyuki Yamamoto,Kazuhiko Nakagawa,Yoichi Nakanishi +19 more
TL;DR: In terms of the primary end point of OS, no statistically significant benefit was observed; however, PFS in the total patient population and OS in patients with wild-type EGFR was prolonged with the addition of pemetrexed to bevacizumab maintenance therapy.
Journal ArticleDOI
A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).
Noboru Yamamoto,Nobuyuki Katakami,Shinji Atagi,Toyoaki Hida,Koichi Goto,Takeshi Horai,Akira Inoue,Yukito Ichinose,Kazuyuki Kobayashi,Kentaro Takeda,Katsuyuki Kiura,Hideo Saka,Tomoki Tamura,Isamu Okamoto,Naoyuki Nogami,R. Morinaga,Kazuto Nishio,Yoko Seki,R. M. Lorence,Mehdi Shahidi +19 more
TL;DR: Afatinib (A), an irreversible erbB family blocker, has preclinical activity against T790M and largely meet criteria for acquired resistance to first generation EGFR TKIs in NSCLC.
Journal ArticleDOI
Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells.
Wataru Okamoto,Isamu Okamoto,Tokuzo Arao,Kazuyoshi Yanagihara,Kazuto Nishio,Kazuhiko Nakagawa +5 more
TL;DR: The data show that activated STAT3 contributes to either cell survival or motility in gastric cancer cells, and that these actions are related to different mechanisms of STAT3 activation.